A combination of nilotinib and A-1331852 was more potent than either A-1331852 or nilotinib alone in displacing BIM from BCL-XL (Figure 5d), further suggesting that A-1331852 can be effective in inducing apoptosis in CML cell lines, either as a single agent or in combination with TKIs. This evidence concerns the gene BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive.